Takeda kicks off JPM week with M&A — buying out another gamma/delta spinout and diving into a new ‘swim lane’
Less than 3 months after Takeda scooped up GammaDelta in a bid to expand its work on next-gen cell therapies, the pharma giant is back — starting off JP Morgan week with another acquisition in the field.
This time, the buyout target is Adaptate Biotherapeutics and its preclinical work on an antibody-based γδ T cell engager platform, a spinout from GammaDelta that Takeda believes gives them a shot at leading the pack in cell therapies.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,500+ biopharma pros reading Endpoints daily — and it's free.